EGFR and non-small cell lung carcinoma: For example, this survey was conducted from May 2020 to August 2020, before the approval of osimertinib as adjuvant treatment for patients with resected EGFR-mutated NSCLC and additional evidence for immunotherapies, such as the CheckMate 816 study, emerged.